🔴 BeyondSpring is trading 10.64% down today after Q2 report showed $6.5 million in liquidity

BeyondSpring is trading 10.64% down now at $0.75 as investors continue reacting to its August 14 second-quarter report and liquidity concerns.

• The clinical-stage company posted a $1.8 million net loss; cash, cash equivalents, and short-term investments totaled $6.5 million, down from $12.6 million at December 31, 2025.
• Management provided no formal financial outlook while preparing the DUBLIN-4 Phase 3 trial.
• Shares fell 15.78% on August 14 amid a mixed broader market, suggesting company-specific earnings and liquidity concerns are the primary catalyst.